Effects of N fraction after mogamulizumab administration. (A-D) Values of N fraction (%) (A), abnormal lymphocytes (%) (B), sIL-2R (C), and LDH (D) after 1 course of chemotherapy, comparison between with (n = 7) and without (n = 52) mogamulizumab administration. (E) Proportion of N fraction at the best response after chemotherapy with (left) and without (right) mogamulizumab administration is compared according to whether or not the patients subsequently relapsed/got refractory. (F) Values of sIL-2R at the best response after mogamulizumab administration among patients with N fraction ≤10% (n = 24) is compared according to whether or not the patients subsequently relapsed/got refractory. (G-H) OS (G) and PFS (F) of 2 groups of patients with aggressive ATL separated by N fraction of 80% at best response after chemotherapy without mogamulizumab (n = 44). (I-J) OS (I) and PFS (J) of 2 groups of patients with aggressive ATL separated by N fraction of 10% at the best response after chemotherapy, including mogamulizumab (n = 30). All data are shown as the mean ± standard deviation; P values were calculated by 2-tailed unpaired Student t test for panels A-F and log-rank test for panels G-J. Mog, mogamulizumab; N.S., not significant.